Introduction
To explore the first and only GIP & GLP-1 receptor agonist for T2D management
Objectives
the first GIP & GLP-1 receptor agonist through an engaging discussion with investigators covering MoA, Phase III SURPASS trial program and appropriate patient.
This Course For :
Physician
( Endocrinology & Metabolism , Family Medicine , Internal Medicine , General practitioner )
Resident / Fellow
( Endocrinology & Metabolism , Family Medicine , Internal Medicine , General practitioner )
Speaker
- Dr. Bruno Halpern
Chief-Director, Obesity Centre, Hospital 9 de Julho, São Paulo
Prof. Dr. Juris J. Meier
Researcher, Diabetes Center Bochum-Hattingen,
St. Josef Hospital, Bochum
Dr. Santiago Tofé
Sr. Consultant, Dep. of Endocrinology, Uni. Hospital Son Espases, Ass. Professor University Illes Balears
Sponsored by :
Price
Course Fee
FREE
FREE
Contact Information
Organization : Virtual Medical AcademyPhone : 920008161
Email : [email protected]
Free
05 Jul 2023 To 05 Jul 2023 -
09:00 PM To 10:00 PM 
Certificate Available 
Online Click Here
- 905
Add to Calendar
07/05/2023 09:00 PM
07/05/2023 10:00 PM
Asia/ Riyadh
Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment
Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment
https://medicalacademy.org/portal/event/view/1983
